Mold-Tek Packaging Ltd Q4 FY25 Earnings Analysis

Published 1 Jun 2026 | Market Cap: ₹2.3K Cr

Price

₹692

Market Cap

₹2.3K Cr

P/E Ratio

30.0

Earnings Summary

Pharma segment expected to see 2.3x to 3x growth in next financial year, targeting Rs. The company expects at least a 15% volume growth in FY ‘26 with EBITDA per kg targeting between Rs.

📊 Revenue & Sales Performance

→Pharma segment expected to see 2.3x to 3x growth in next financial year, targeting Rs. 30+ crores in FY26 and Rs. 50+ crores in FY27.
→Pharma volumes aimed at 3,000 tons per annum by end of FY26, with revenue potential of Rs. 90-100 crores.
→Paint segment growth in FY26 expected to reach double digits (~10%) driven by capacity expansions and increased IML adoption by Asian Paints.
→Food & FMCG segment targeting 15%-20% growth in FY26 due to enhanced printing capacity and new client additions.
→Overall company volume growth target for FY26 is around 15%.
→EBITDA per kg expected to improve, with internal targets around Rs. 41-42 per kg in FY26, driven by pharma and food/FMCG segments.
→Capacity utilization improving in key plants (up to 75-80% in April).
→Export opportunities in pharma expected to start contributing within 1-2 years, including US and European markets.

📈 Profitability & Margins

→The company expects at least a 15% volume growth in FY ‘26 with EBITDA per kg targeting between Rs. 41 and Rs. 42. (Page 12)
→EBITDA per kg is anticipated to rise toward Rs. 42-43 in the next quarters, driven by higher margin segments like Pharma and Food. (Page 9)
→Pharma division, which reached breakeven in Q4 FY ‘25, is expected to grow from Rs. 11 crores to Rs. 30-35 crores in FY ‘26 and potentially Rs. 50+ crores in FY ‘27, contributing significantly to EBITDA margin improvement. (Pages 6, 4)
→Paint segment growth is expected to improve to double-digits (~10%) in FY ‘26 due to enhanced capacities and increased IML adoption by Asian Paints and ABG. (Page 5)
→Overall EBITDA growth will benefit from strong growth and high margins in Food & FMCG and Pharma segments, along with stabilized paint segment performance. (Pages 9, 7)
→PAT had a slight 9% dip last year but future outlook is positive given operational improvements and product mix. (Page 3)

🏗️ Capital Expenditure Plans

→FY '26 CAPEX is guided between Rs. 70 to 80 crores, partly for pharma and printing expansion.
→Pharma segment is getting Rs. 20-25 crores for land acquisition and building completion at Sultanpur.
→Existing Sultanpur facility capacity being expanded from 1,500 tons to 3,000 tons per annum by March 2026.
→New land (~2.5 acres) acquired adjacent to Sultanpur for future pharma expansion beyond 3,000 tons capacity.
→Additional machines (injection molding, printing) being added; 5 new injection molding machines to arrive by June.
→Printing capacity increased by 70% with investments of over Rs. 25 crores in the previous financial year.
→ABG (Aditya Birla Group) capacity enhanced with Brownfield expansion, operating fully from March-April 2025.
→Strategic focus on pharma growth: expecting 2.3x to 3x pharma revenue growth next financial year; exploring export opportunities.
→IML facility expanded across Asian Paints' plants, supporting growth.
→CAPEX carefully controlled to Rs. 70-80 crore for FY ‘26 despite higher spend in FY ‘25 (~Rs. 140 crores).

💰 Fundraising & Capital Structure

→The company plans to keep CAPEX for FY ‘26 between Rs. 70 to 80 crores, primarily for pharma capacity expansion, building completion, and printing enhancement.
→No explicit mention of new fundraising through debt or equity in the transcript.
→The management indicates a cautious but confident approach towards investments, especially in pharma, with ongoing land acquisitions for future expansions.
→There is no direct statement about raising funds via debt or equity at present or in near future during the call.

📋 Order Book & Pipeline

The transcript from the Mold-Tek Packaging Limited conference call on May 19, 2025, does not explicitly mention details about the current or expected order book or pending orders. However, some relevant insights include: - The Pharma division showed strong growth, with a 3x turnover increase in Q4 and a base established for future quarters, indicating a healthy order inflow. - Capacity utilization improvements at ABG and various plants (e.g., Satara running at 75%-80% capacity in April) suggest increasing order volumes. - Asian Paints has progressively shifted brands into IML, enhancing order volumes for Mold-Tek across multiple plants. - The company expects double-digit growth in the Paint segment and 15%-20% growth in the Food and FMCG segment for FY26, implying a positive order pipeline. - New client additions in Food & FMCG (e.g., Marico, Mankind) also indicate growing demand. No explicit quantitative orderbook or pending order figures were disclosed.

Key Metrics

Frequently Asked Questions

What were Mold-Tek Packaging Ltd Q4 FY25 results?

Pharma segment expected to see 2.3x to 3x growth in next financial year, targeting Rs. The company expects at least a 15% volume growth in FY ‘26 with EBITDA per kg targeting between Rs.

What is Mold-Tek Packaging Ltd share price analysis?

Mold-Tek Packaging Ltd currently shows a neutral. The stock trades at a P/E of 30.0 with a market cap of ₹2,278 Cr. Investors should review the full earnings analysis for detailed insights.

Is Mold-Tek Packaging Ltd planning capital expenditure?

FY '26 CAPEX is guided between Rs.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.